Neglected tropical diseases

STATEMENT -- On the recent opinion of the European Medicines Agency on fexinidazole treatment for gambiense human African trypanosomiasis


22 November 2018 | Geneva −− The World Health Organization (WHO) welcomes the positive scientific opinion adopted by the European Medicines Agency’s Committee for Medicinal Products for Human Use on fexinidazole as the first comprehensive oral treatment for gambiense human African trypanosomiasis (sleeping sickness).

The Agency’s stance brings a new tool that can both simplify and facilitate case management and contribute to achieving the goal of elimination of human African trypanosomiasis as a public health problem, as new cases of the disease continue to decline, reaching historically low levels.

WHO wishes to thank all the donor agencies, foundations, partners, pharmaceutical companies, funders and stakeholders for their sustained support and collaboration.

WHO has started work on updating treatment guidelines that will define the role of fexinidazole in the current therapeutic arsenal.

As a next step – and capitalizing on the experience and delivery mechanism for medicines of the past two decades – WHO will work closely with all partners to ensure the timely distribution of the medicine and ensure that appropriate training is provided to health professionals for the informed and skilled use of fexinidazole.


Ashok Moloo

WHO/HTM/NTD
Telephone: +41 22 791 1637
Mobile phone: +41 79 540 50 86
molooa@who.int